Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 266 results found since Jan 2013.
Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report
ConclusionOwing to the link between coronavirus disease 2019 and hematologic cancers with hypercoagulopathy and the tendency of patients with leukemia to have coronavirus disease 2019 complications, children with leukemia as well as suspected coronavirus disease 2019 must be hospitalized to prevent blood clot formation.
Source: Journal of Medical Case Reports - December 6, 2022 Category: General Medicine Source Type: research
Methotrexate-Induced Stroke-Like Encephalopathy: Beware the Stroke Mimic
We report a case of methotrexate (MTX)-induced stroke-like encephalopathy in an 18-year-old woman, with acute lymphoblastic leukemia, who developed a sudden neurological deficit mimicking a cerebrovascular event. Bain MRI showed hyperintensities on diffusion-weighted-imaging (DWI) with matching apparent diffusion coefficient hypointensities, which also represent the commonest MRI findings in acute cerebral infarction. DWI changes spared the cerebral cortex and did not respect vascular territories, supporting a non-vascular mechanism. MRI plays a crucial role in the diagnostic work-up and is essential to avoid unnecessar...
Source: Journal of the Belgian Society of Radiology - October 31, 2022 Category: Radiology Source Type: research
Influence of clonal hematopoiesis on non-hematological diseases and aging processes
Inn Med (Heidelb). 2022 Oct 10. doi: 10.1007/s00108-022-01409-6. Online ahead of print.ABSTRACTThe occurrence of clonal hematopoiesis, caused by acquired somatic mutations of leukemia-associated genes in blood stem cells is very common in the population and increases with age. Besides an increased risk of developing myeloid neoplasms, an unexpected causal relationship between clonal hematopoiesis and cardiovascular diseases was recently discovered. Clonal hematopoiesis presents as a new independent and strong risk factor for cardiovascular diseases, such as atherosclerosis, coronary heart disease, heart failure, aortic val...
Source: Atherosclerosis - October 10, 2022 Category: Cardiology Authors: Michael A Rieger Source Type: research
Identifying potential therapeutic targets for ischemic stroke through immune infiltration analysis and construction of a programmed cell death ‑related ceRNA network
Exp Ther Med. 2022 Sep 21;24(5):680. doi: 10.3892/etm.2022.11616. eCollection 2022 Nov.ABSTRACTThe present study aimed to uncover the underlying mechanisms and potential intervention targets of ischemic stroke (IS). An immune cell infiltration analysis using CIBERSORT was performed on two stroke-related datasets from the Gene Expression Omnibus database to generate a competitive endogenous RNA (ceRNA) network. Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to predict potential biological functions of the network. Differentially expressed genes in the ceRNA net...
Source: Experimental and Therapeutic Medicine - October 3, 2022 Category: General Medicine Authors: Yiteng Cui Xin Zhou Pingping Meng Shanshan Dong Ziwei Wang Tongye Liu Xiaomin Liu Yunteng Cui Yuyang Wang Qiang Wang Source Type: research
Poster: CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Qing Huang, Sumeet Panjabi, Annalise Hilts, Stephanie Lu, Marie-H élène Lafeuille, Patrick Lefebvre, Michael Choi Tags: LEUKEMIA & RELATED MALIGNANCIES Source Type: research
CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study
Context: Atrial fibrillation (AF) is a recognized adverse consequence associated with all Bruton's tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); however, real-world time to discontinuation (TTD) and time to next treatment (TTNT) of CLL/SLL patients with a high baseline AF risk remain unknown. Objective: To describe TTNT and TTD for CLL/SLL patients who initiated a first-line (1L) or second-or-later-line (2L+) therapy with ibrutinib or other regimens, in all patients and for subsets of patients with high baseline risk of AF/AF-related events.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Anna Narezkina, Nausheen Akhter, Xiaoxiao Lu, Bruno Emond, Qing Huang, Sumeet Panjabi, Annalise Hilts, Stephanie Lu, Marie-H élène Lafeuille, Patrick Lefebvre, Michael Choi Tags: Acute Lymphoblastic Leukemia Source Type: research
Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
CONCLUSION: This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens.PMID:35973891 | DOI:10.1016/j.clml.2022.07.004
Source: Clinical Lymphoma and Myeloma - August 16, 2022 Category: Cancer & Oncology Authors: Anna Narezkina Nausheen Akhter Xiaoxiao Lu Bruno Emond Sumeet Panjabi Shaun P Forbes Annalise Hilts Stephanie Liu Marie-H élène Lafeuille Patrick Lefebvre Qing Huang Michael Choi Source Type: research
